Home Cart Sign in  
Chemical Structure| 1424635-83-5 Chemical Structure| 1424635-83-5

Structure of TRULI
CAS No.: 1424635-83-5

Chemical Structure| 1424635-83-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

TRULI (Lats-IN-1) is a potent, ATP-competitive inhibitor of Lats1 and Lats2 kinases, promoting Yap-dependent proliferation in postmitotic mammalian tissue.

Synonyms: Lats-IN-1; LATS Inhibitor 1; TRULI, Lats-IN-1, LATS Inhibitor 1

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of TRULI

CAS No. :1424635-83-5
Formula : C18H14N4OS
M.W : 334.40
SMILES Code : O=C(C1=CNC2=NC=CC=C21)/N=C3SC=CN\3CC4=CC=CC=C4
Synonyms :
Lats-IN-1; LATS Inhibitor 1; TRULI, Lats-IN-1, LATS Inhibitor 1
MDL No. :MFCD33402276
InChI Key :VTXBMVZVPUSAJF-UHFFFAOYSA-N
Pubchem ID :71890885

Safety of TRULI

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of TRULI

Hippo

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
SLE keratinocytes 10 µM 24 hours Inhibition of LATS1/2 kinase activity, reducing UVB-induced apoptosis PMC10313771
human retinal organoids 10 μM 24 hours To test the inhibitory effect of TRULI on Yap phosphorylation in human retinal organoids, showing a significant 30% reduction in Yap phosphorylation. PMC9282237
human embryonic stem cells (hESCs) 10 µM 24 hours TRULI inhibits YAP phosphorylation, enhances YAP nuclear localization, and promotes the differentiation of non-neural ectoderm (NNE). PMC9033270
chondrocytes 10, 25, 50 μM 48 hours TRULI restored IL-1β-induced reduction in ECM synthesis and blocked abnormal ECM degradation by inhibiting LATS1 phosphorylation PMC11897192
K562 cells 30 µM or greater 48 hours TRULI significantly reduced the clonogenicity, migratory capacity, and ROS production of K562 cells, indicating its inhibition of the tumorigenic properties of CML cells. PMC10874434
neural crest (NC) cells 10 µM TRULI treatment resulted in the complete loss of neural crest (NC) cells and a significant increase in the expression of the epidermal marker KRT18. PMC9033270

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice DMM-induced osteoarthritis model intra-articular injection 5 mg/mL twice a week for 8 weeks TRULI improved abnormal behavior post-DMM surgery, reduced cartilage degeneration, and restored ECM balance PMC11897192
Mice CK14-CreERT2 or Slc1a3-CreERT mice Ocular surface administration 20 μM Every 8 hours for 4 consecutive days TRULI inhibited the de-differentiation of CECs, indicating the important role of the Hippo/YAP pathway in the de-differentiation of CECs. PMC11578144
Mice cardiac cryolesion model intraperitoneal injection 200 mg/kg single injection, lasting 4 hours To test the inhibitory effect of TDI-011536 on Yap phosphorylation in mice, showing a significant reduction in Yap phosphorylation in the heart, liver, and skin, with the effect lasting 4 hours. PMC9282237

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.99mL

0.60mL

0.30mL

14.95mL

2.99mL

1.50mL

29.90mL

5.98mL

2.99mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories